Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Innate Pharma (IPHA) Equity Average (2018 - 2025)

Historic Equity Average for Innate Pharma (IPHA) over the last 8 years, with Q2 2025 value amounting to $7.6 million.

  • Innate Pharma's Equity Average fell 8242.68% to $7.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $7.6 million, marking a year-over-year decrease of 8242.68%. This contributed to the annual value of $32.9 million for FY2024, which is 4101.46% down from last year.
  • Innate Pharma's Equity Average amounted to $7.6 million in Q2 2025, which was down 8242.68% from $20.2 million recorded in Q4 2024.
  • Innate Pharma's Equity Average's 5-year high stood at $173.4 million during Q2 2021, with a 5-year trough of $7.6 million in Q2 2025.
  • Over the past 5 years, Innate Pharma's median Equity Average value was $59.4 million (recorded in 2023), while the average stood at $79.8 million.
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 9986.35% in 2021, then tumbled by 2655.55% in 2024.
  • Innate Pharma's Equity Average (Quarter) stood at $141.9 million in 2021, then crashed by 36.78% to $89.7 million in 2022, then crashed by 33.74% to $59.4 million in 2023, then crashed by 65.97% to $20.2 million in 2024, then plummeted by 62.27% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q2 2025, $20.2 million for Q4 2024, and $43.4 million during Q2 2024.